Science ❯ Biotechnology

Drug Discovery

Clinical Research Artificial Intelligence Clinical Trials AI Applications AI in Healthcare AI in Medicine Recombinant Cells Small Molecule Drugs Cancer Research Antibody Development Therapeutics Clinical Studies Computational Modeling Virtual Cell Modeling Global Firms Kinase Inhibitors Optogenetics Targeted Therapy Molecular Simulation Therapeutic Agents Proprietary Platforms Bioengineering Precision Therapies Small Molecule Therapies Regulatory Science Molecular Licensing Antibody-Drug Conjugates

Biogen to Buy RayThera for Up to $1 Billion

The acquisition adds small-molecule anti-inflammatory candidates to Biogen’s pipeline with most payments tied to clinical and regulatory milestones.

Novartis Strikes $2 Billion Deal for Mutant-Selective PI3Kα Cancer Drug SNV4818

FDA Grants Breakthrough Therapy Designation to Biogen’s Litifilimab for Cutaneous Lupus

Amgen Buys Oxford Spinout Dark Blue Therapeutics for Up to $840 Million

Chai Discovery Raises $130 Million Series B at $1.3 Billion Valuation

Google Launches Interactions API and Upgraded Gemini Deep Research for Developers

Eli Lilly Halts Diabetes Arm of Bimagrumab Obesity Trial Weeks After Launch

Integrated Biosciences’ Optogenetic Platform Advances Toward Aging and Pan-Antiviral Therapies